42
Participants
Start Date
October 30, 2024
Primary Completion Date
August 31, 2028
Study Completion Date
September 30, 2028
Zanubrutinib
160 mg, administered twice daily from Day 1 to Day 28 (D1-D28)
Rituximab
375 mg/m², administered once a week during Cycle 1 (C1), and on Day 1 (D1) of Cycles 2-6 (C2-C6)
RECRUITING
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou
Fifth Affiliated Hospital, Sun Yat-Sen University
OTHER
Gansu Cancer Hospital
OTHER
Fifth Affiliated Hospital of Guangzhou Medical University
OTHER
Beijing Tongren Hospital
OTHER
Tongji Medical College of Huazhong University of Science & Technology
UNKNOWN
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Shenzhen People's Hospital
OTHER
Sun Yat-sen University
OTHER